美国血液技术 HAE 深 沪
等待开盘 04-02 09:30:00 美东时间
56.24
-0.120
-0.21%
华盛通- 最 高56.97
- 今 开56.28
- 成交量 35.87万股
- 最 低 55.94
- 昨 收 56.36
- 总市值 26.14亿
- 52周最高 87.32
- 市盈率 静 17.02
- 换手率 0.77%
- 52周最低 47.315
- 委 比 -11.11%
- 总股本 4647.14万
- 历史最高 142.11
- 量 比 0.43
- 振 幅 1.83%
- 历史最低 25.98
- 每 手 1
- 风险率 10.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Haemonetics Receives FDA Approval To Expand Labeling For VASCADE MVP XL Venous Vascular Closure System
Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to
03-31 04:18
新浪财经ESG：美国血液技术 MSCI（明晟）ESG评级调升至AA
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:22
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Citigroup Maintains Neutral on Haemonetics, Lowers Price Target to $70
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price target from $75 to $70.
03-11 23:39
BRIEF-Haemonetics Corp - Repays Outstanding 0.00% Convertible Senior Notes - SEC Filing
BRIEF-Haemonetics Corp - Repays Outstanding 0.00% Convertible Senior Notes - SEC Filing March 3 (Reuters) - SEC Filing: HAEMONETICS CORP - REPAYS OUTSTANDING 0.00% CONVERTIBLE SENIOR NOTES - SEC FILING HAEMONETICS CORP - PAYS $300 MILLION FOR OUTSTANDING NOTES - SEC FILING HAEMONETICS CORP - REPAYME
03-03 20:54
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
Haemonetics ( ($HAE) ) has shared an announcement. On March 2, 2026, Haemonetic...
03-03 19:28
Haemonetics Repays $300 Million Convertible Notes at Maturity
Haemonetics Repays $300 Million Convertible Notes at Maturity Haemonetics Corporation said it repaid in full at maturity its 0.00% Convertible Senior Notes due 2026, paying $300 million in cash for the outstanding principal. The repayment was funded with cash on hand and borrowings under its revolvi
03-03 19:09
FDA clears Haemonetics NexSys PCS plasma system with Persona PLUS technology
FDA clears Haemonetics NexSys PCS plasma system with Persona PLUS technology Haemonetics Corporation said the U.S. Food and Drug Administration granted 510(k) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology. The company stated the clearance was supported by clinica
02-24 05:16
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences has appointed Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer. These seasoned executives bring extensive experience in MedTech innovation, legal affairs, and quality management. The creation of the CTO role highlights Integra's commitment to advancing R&D and fostering long-term growth.
02-17 13:30
Analysts’ Top Healthcare Picks: Haemonetics (HAE), Waters (WAT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
02-10 20:20
